Please assess the completion status of the following clinical trial:

Trial Title: A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented urothelial carcinoma (squamous differentiation or mixed cell types allowed).~* Metastatic disease or locally advanced disease that is not resectable.~* Must have received prior treatment with a CPI in the locally advanced or metastatic urothelial cancer setting. A CPI is defined as a programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. Patients who received CPI therapy in the neoadjuvant/adjuvant setting and had recurrent or progressive disease either during therapy or within 3 months of therapy completion are eligible.~* Must either have prior treatment with platinum-containing chemotherapy (Cohort 1) or be platinum-naïve and ineligible for treatment with cisplatin at time of enrollment (Cohort 2).~* Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.~* Tumor tissue samples must be available for submission to the sponsor prior to study treatment.~* Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1).~* An Eastern Cooperative Oncology Group (ECOG) Performance Status score of ≤1 for Cohort 1 or ≤2 for Cohort 2.~* Anticipated life expectancy of ≥3 months as assessed by the investigator.~Exclusion Criteria:~* Ongoing sensory or motor neuropathy Grade ≥2.~* Active central nervous system (CNS) metastases.~* Immunotherapy related myocarditis, colitis, uveitis, or pneumonitis.~* Prior enrollment in an enfortumab vedotin study or prior treatment with other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs).~* Uncontrolled tumor-related pain or impending spinal cord compression.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enfortumab vedotin (Type: EXPERIMENTAL): Enfortumab vedotin on days 1, 8 and 15 every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).